Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 2
2007 1
2008 2
2009 1
2010 2
2011 1
2012 2
2013 3
2014 2
2015 1
2016 3
2017 3
2018 2
2019 3
2020 3
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
Salvi S, Varesano S, Boccardo S, Ravetti JL, Canessa PA, Pistillo MP, Ferro P, Fedeli F, Roncella S. Salvi S, et al. Among authors: roncella s. J Thorac Oncol. 2017 Aug;12(8):e116-e118. doi: 10.1016/j.jtho.2017.03.015. J Thorac Oncol. 2017. PMID: 28748818 Free article. No abstract available.
IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade.
Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Venè R, Poggi A, Roncella S. Pistillo MP, et al. Among authors: roncella s. Cell Mol Immunol. 2020 Apr;17(4):410-411. doi: 10.1038/s41423-019-0245-x. Epub 2019 Jun 19. Cell Mol Immunol. 2020. PMID: 31217525 Free PMC article. No abstract available.
Amplification of MET in a Patient with Malignant Pleural Mesothelioma.
Varesano S, Salvi S, Boccardo S, Ravetti JL, Ferro P, Canessa PA, Fedeli F, Pistillo MP, Roncella S. Varesano S, et al. Among authors: roncella s. J Thorac Oncol. 2015 Oct;10(10):e103-4. doi: 10.1097/JTO.0000000000000638. J Thorac Oncol. 2015. PMID: 26398828 Free article. No abstract available.
Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score.
Grosso F, Mannucci M, Ugo F, Ferro P, Cassinari M, Vigani A, De Angelis AM, Delfanti S, Lia M, Guaschino R, Barbero S, Roncella S, Giannoni U, Bertolotti M, Pistillo MP, Fontana V. Grosso F, et al. Among authors: roncella s. Diagnostics (Basel). 2021 Oct 29;11(11):2015. doi: 10.3390/diagnostics11112015. Diagnostics (Basel). 2021. PMID: 34829362 Free PMC article.
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP. Carosio R, et al. Among authors: roncella s. J Cancer Res Clin Oncol. 2021 Feb;147(2):459-468. doi: 10.1007/s00432-020-03457-7. Epub 2020 Nov 20. J Cancer Res Clin Oncol. 2021. PMID: 33216211
33 results